Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,698.40
(
-0.41%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
111.71
(
4.81%
)
Bitcoin
70,043.07
(
-1.68%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 61472

Wednesday, 04/16/2008 5:42:08 PM

Wednesday, April 16, 2008 5:42:08 PM

Post# of 257257
More notes from GILD CC:

GS9190 in HCV: dosing resumed in phase-1b trial at 40mg to ascertain the QT-prolongation before deciding whether to proceed to phase-2.

Elvitegravir in HIV: co-formulation with Truvada and a proprietary boosting agent called GS9350 has been achieved. If GS9350 passes monotherapy safety studies, it will supersede ritonavir as the boosting agent of choice for further development of elvitegravir.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now